FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1285-1292 October 29, 1998 Number 18 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Angiotensin-converting–enzyme (ACE) inhibitors not only decrease the production of angiotensin II but also decrease the degradation of bradykinin. In this study, a specific bradykinin-receptor antagonist, icatibant acetate (HOE 140), was used to determine the contribution of bradykinin to the short-term effects of ACE inhibition on blood pressure and plasma renin activity in both normotensive and hypertensive subjects.

Methods We compared the hemodynamic, renal, and endocrine effects of captopril alone (25 mg), captopril plus icatibant (100 µg per kilogram of body weight), the angiotensin II subtype 1–receptor antagonist losartan (75 mg), and placebo in 20 subjects with normal blood pressure and 7 subjects with hypertension. The subjects were studied while they were salt depleted (i.e., in balance on a diet in which they were allowed 10 mmol of sodium per day). The drugs were administered on four separate study days in a single-blind, randomized fashion.

Results The coadministration of icatibant significantly attenuated the hypotensive effect of captopril (maximal decrease in mean [±SE] arterial pressure for all subjects combined, 10.5±1.0 mm Hg, as compared with 14.0±1.0 mm Hg for captopril alone; P=0.001), in such a way that the decrease in blood pressure after the administration of captopril plus icatibant was similar to that after the administration of losartan (maximal decrease in mean arterial pressure, 11.0±1.7 mm Hg). Icatibant did not alter the renal hemodynamic response to captopril, but it significantly altered the change in plasma renin activity in response to ACE inhibition (–0.4±0.4 ng of angiotensin I per milliliter per hour, as compared with 2.0±0.7 ng per milliliter per hour for captopril alone; P=0.007). The magnitude of these effects was similar in both the normotensive and the hypertensive subjects, as well as in both the black subjects and the white subjects.

Conclusions These data confirm that bradykinin contributes to the short-term effects of ACE inhibition on blood pressure in normotensive and hypertensive persons and suggest that bradykinin also contributes to the short-term effects of ACE inhibition on the renin–angiotensin system.

Source Information

From the Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville.

Address reprint requests to Dr. Brown at the Division of Clinical Pharmacology, 560 MRB-1, Vanderbilt University Medical Center, Nashville, TN 37232-6602.

Full Text of this Article

Related Letters:

Bradykinin and Inhibition of Angiotensin-Converting Enzyme in Hypertension
Azizi M., Agarwal R., Gallois H., Piot O., Gainer J. V., Brown N. J.
Extract | Full Text  
N Engl J Med 1999; 340:967-969, Mar 25, 1999. Correspondence

This article has been cited by other articles:

• Dietze, G. J, Henriksen, E. J (2008). Review: Angiotensin-converting enzyme in skeletal muscle: sentinel of blood pressure control and glucose homeostasis. Journal of Renin-Angiotensin-Aldosterone System 9: 75-88 [Abstract]  
• Duka, A., Kintsurashvili, E., Duka, I., Ona, D., Hopkins, T. A., Bader, M., Gavras, I., Gavras, H. (2008). Angiotensin-Converting Enzyme Inhibition After Experimental Myocardial Infarct: Role of the Kinin B1 and B2 Receptors. Hypertension 51: 1352-1357 [Abstract] [Full Text]  
• McMurray, J. J.V. (2008). ACE Inhibitors in Cardiovascular Disease -- Unbeatable?. NEJM 358: 1615-1616 [Full Text]  
• Van Guilder, G. P., Pretorius, M., Luther, J. M., Byrd, J. B., Hill, K., Gainer, J. V., Brown, N. J. (2008). Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition. Hypertension 51: 454-459 [Abstract] [Full Text]  
• Augustyniak, R. A., Maliszewska-Scislo, M., Chen, H., Fallucca, J., Rossi, N. F. (2007). Acute angiotensin-converting enzyme inhibition evokes bradykinin-induced sympathetic activation in diabetic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R2260-R2266 [Abstract] [Full Text]  
• LeFebvre, J., Shintani, A., Gebretsadik, T., Petro, J. R., Murphey, L. J., Brown, N. J. (2007). Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade. J. Pharmacol. Exp. Ther. 320: 1261-1267 [Abstract] [Full Text]  
• Vinik, A. I., Ziegler, D. (2007). Diabetic Cardiovascular Autonomic Neuropathy. Circulation 115: 387-397 [Full Text]  
• Murphey, L. J., Malave, H. A., Petro, J., Biaggioni, I., Byrne, D. W., Vaughan, D. E., Luther, J. M., Pretorius, M., Brown, N. J. (2006). Bradykinin and Its Metabolite Bradykinin 1-5 Inhibit Thrombin-Induced Platelet Aggregation in Humans. J. Pharmacol. Exp. Ther. 318: 1287-1292 [Abstract] [Full Text]  
• Biyashev, D., Tan, F., Chen, Z., Zhang, K., Deddish, P. A., Erdos, E. G., Hecquet, C. (2006). Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am. J. Physiol. Heart Circ. Physiol. 290: H1244-H1250 [Abstract] [Full Text]  
• Zamorano, R., Suchindran, S., Gainer, J. V. (2006). 3'-Untranslated region of the type 2 bradykinin receptor is a potent regulator of gene expression. Am. J. Physiol. Renal Physiol. 290: F456-F464 [Abstract] [Full Text]  
• Jawa, A., Nachimuthu, S., Pendergrass, M., Asnani, S., Fonseca, V. (2006). Impaired Vascular Reactivity in African-American Patients with Type 2 Diabetes Mellitus and Microalbuminuria or Proteinuria Despite Angiotensin-Converting Enzyme Inhibitor Therapy. J. Clin. Endocrinol. Metab. 91: 31-35 [Abstract] [Full Text]  
• Chen, Z., Tan, F., Erdos, E. G., Deddish, P. A. (2005). Hydrolysis of Angiotensin Peptides by Human Angiotensin I-Converting Enzyme and the Resensitization of B2 Kinin Receptors. Hypertension 46: 1368-1373 [Abstract] [Full Text]  
• van de Wal, R. M.A., van Veldhuisen, D. J., van Gilst, W. H., Voors, A. A. (2005). Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. Eur Heart J 26: 2361-2367 [Abstract] [Full Text]  
• Valenti, C., Cialdai, C., Giuliani, S., Lecci, A., Tramontana, M., Meini, S., Quartara, L., Maggi, C. A. (2005). MEN16132, a Novel Potent and Selective Nonpeptide Kinin B2 Receptor Antagonist: In Vivo Activity on Bradykinin-Induced Bronchoconstriction and Nasal Mucosa Microvascular Leakage in Anesthetized Guinea Pigs. J. Pharmacol. Exp. Ther. 315: 616-623 [Abstract] [Full Text]  
• Ahmed, S. B., Hovind, P., Parving, H.-H., Rossing, P., Price, D. A., Laffel, L. M., Lansang, M. C., Stevanovic, R., Fisher, N. D.L., Hollenberg, N. K. (2005). Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy. Diabetes Care 28: 1988-1994 [Abstract] [Full Text]  
• Cruden, N. L.M., Tse, G. H., Fox, K. A.A., Ludlam, C. A., Megson, I., Newby, D. E. (2005). B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure. Arterioscler. Thromb. Vasc. Bio. 25: 772-777 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2005). Diabetic Nephropathy. Diabetes Care 28: 745-751 [Full Text]  
• Leeb-Lundberg, L. M. F., Marceau, F., Muller-Esterl, W., Pettibone, D. J., Zuraw, B. L. (2005). International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences. Pharmacol. Rev. 57: 27-77 [Abstract] [Full Text]  
• Epstein, B. J, Gums, J. G (2005). Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations. The Annals of Pharmacotherapy 39: 470-480 [Abstract] [Full Text]  
• Boix, F., Roe, C., Rosenborg, L., Knardahl, S. (2005). Kinin peptides in human trapezius muscle during sustained isometric contraction and their relation to pain. J. Appl. Physiol. 98: 534-540 [Abstract] [Full Text]  
• Roden, D. M. (2005). An Underrecognized Challenge in Evaluating Postmarketing Drug Safety. Circulation 111: 246-248 [Full Text]  
• Campbell, D. J., Krum, H., Esler, M. D. (2005). Losartan Increases Bradykinin Levels in Hypertensive Humans. Circulation 111: 315-320 [Abstract] [Full Text]  
• Gardiner, S. M., March, J. E., Kemp, P. A., Ballard, S. A., Hawkeswood, E., Hughes, B., Bennett, T. (2005). Hemodynamic Effects of Phosphodiesterase 5 and Angiotensin-Converting Enzyme Inhibition Alone or in Combination in Conscious SHR. J. Pharmacol. Exp. Ther. 312: 265-271 [Abstract] [Full Text]  
• Cruden, N. L.M., Fox, K. A.A., Ludlam, C. A., Johnston, N. R., Newby, D. E. (2004). Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition. Hypertension 44: 913-918 [Abstract] [Full Text]  
• Bascands, J.-L., Schanstra, J. P. (2004). Bradykinin and Renal Fibrosis: Have We ACE'd it?. J. Am. Soc. Nephrol. 15: 2504-2506 [Full Text]  
• Cruden, N. L.M., Witherow, F. N., Webb, D. J., Fox, K. A.A., Newby, D. E. (2004). Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure. Arterioscler. Thromb. Vasc. Bio. 24: 1043-1048 [Abstract] [Full Text]  
• Fournier, A., Messerli, F. H., Achard, J. M., Fernandez, L. (2004). Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43: 1343-1347 [Abstract] [Full Text]  
• Unger, T., Jun Li, (2004). The role of the renin-angiotensin-aldosterone system in heart failure. Journal of Renin-Angiotensin-Aldosterone System 5: S7-S10 [Abstract]  
• Murphey, L. J., Eccles, W. K., Williams, G. H., Brown, N. J. (2004). Loss of Sodium Modulation of Plasma Kinins in Human Hypertension. J. Pharmacol. Exp. Ther. 308: 1046-1052 [Abstract] [Full Text]  
• Tschope, C., Spillmann, F., Altmann, C., Koch, M., Westermann, D., Dhayat, N., Dhayat, S., Bascands, J.-L., Gera, L., Hoffmann, S., Schultheiss, H.-P., Walther, T. (2004). The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res 61: 559-569 [Abstract] [Full Text]  
• McFarlane, S. I., Winer, N., Sowers, J. R. (2003). Role of the Natriuretic Peptide System in Cardiorenal Protection. Arch Intern Med 163: 2696-2704 [Abstract] [Full Text]  
• Narita, I, Goto, S, Saito, N, Song, J, Omori, K, Kondo, D, Sakatsume, M, Gejyo, F (2003). Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism. J. Med. Genet. 40: e130-130 [Full Text]  
• Brunner-La Rocca, H. P. (2003). Interaction of Angiotensin-Converting Enzyme Inhibition and Aspirin in Congestive Heart Failure: Long Controversy Finally Resolved?. Chest 124: 1192-1194 [Full Text]  
• Picciotto, G., Sargiotto, A., Petrarulo, M., Rabbia, C., De Filippi, P. G., Roccatello, D. (2003). Reliability of Captopril Renography in Patients Under Chronic Therapy with Angiotensin II (AT1) Receptor Antagonists. JNM 44: 1574-1581 [Abstract] [Full Text]  
• Meune, C., Mourad, J.-J., Bergmann, J.-F., Spaulding, C. (2003). Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance. Journal of Renin-Angiotensin-Aldosterone System 4: 149-154 [Abstract]  
• Witherow, F. N., Dawson, P., Ludlam, C. A., Webb, D. J., Fox, K. A.A., Newby, D. E. (2003). Bradykinin Receptor Antagonism and Endothelial Tissue Plasminogen Activator Release in Humans. Arterioscler. Thromb. Vasc. Bio. 23: 1667-1670 [Abstract] [Full Text]  
• Jennings, G. (2003). New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?. Eur Heart J Suppl 5: F3-F11 [Abstract]  
• Finnegan, P. M, Gleason, B. L (2003). Combination ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension. The Annals of Pharmacotherapy 37: 886-889 [Abstract] [Full Text]  
• Xiao, H. D., Fuchs, S., Cole, J. M., Disher, K. M., Sutliff, R. L., Bernstein, K. E. (2003). Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting-Enzyme Systems: Role of bradykinin in angiotensin-converting enzyme knockout mice. Am. J. Physiol. Heart Circ. Physiol. 284: H1969-H1977 [Abstract] [Full Text]  
• Jaffa, A. A., Durazo-Arvizu, R., Zheng, D., Lackland, D. T., Srikanth, S., Garvey, W. T., Schmaier, A. H. (2003). Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes. Diabetes 52: 1215-1221 [Abstract] [Full Text]  
• Li, X., Du, Y., Du, Y., Huang, X. (2003). Correlation of Angiotensin-Converting Enzyme Gene Polymorphism with Effect of Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitor. J CARDIOVASC PHARMACOL THER 8: 25-30 [Abstract]  
• Backlund, T., Palojoki, E., Saraste, A., Gronholm, T., Eriksson, A., Lakkisto, P., Vuolteenaho, O., Nieminen, M. S, Voipio-Pulkki, L.-M., Laine, M., Tikkanen, I. (2003). Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc Res 57: 727-737 [Abstract] [Full Text]  
• Campbell, D. J. (2003). Vasopeptidase Inhibition: A Double-Edged Sword?. Hypertension 41: 383-389 [Abstract] [Full Text]  
• Zeitz, C. J., Campbell, D. J., Horowitz, J. D. (2003). Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans. Hypertension 41: 482-487 [Abstract] [Full Text]  
• Pretorius, M., Rosenbaum, D., Vaughan, D. E., Brown, N. J. (2003). Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin. Circulation 107: 579-585 [Abstract] [Full Text]  
• Murphey, L., Vaughan, D., Brown, N. (2003). Contribution of bradykinin to the cardioprotective effects of ACE inhibitors. Eur Heart J Suppl 5: A37-A41 [Abstract]  
• Gewaltig, M. T, Kojda, G. (2002). Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55: 250-260 [Abstract] [Full Text]  
• Sica, D. A (2002). Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. Journal of Renin-Angiotensin-Aldosterone System 3: 66-71 [Abstract]  
• Rosenbaum, D. A., Pretorius, M., Gainer, J. V., Byrne, D., Murphey, L. J., Painter, C. A., Vaughan, D. E., Brown, N. J. (2002). Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin. Arterioscler. Thromb. Vasc. Bio. 22: 1023-1028 [Abstract] [Full Text]  
• Hilgers, K. F., Mann, J. F. E. (2002). ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease. J. Am. Soc. Nephrol. 13: 1100-1108 [Full Text]  
• Morgan, T., Griffiths, C., Delbridge, L. (2002). Interaction of ACE inhibitors and AT1-receptor blockers on maximum blood pressure response in spontaneous hypertensive rats. Journal of Renin-Angiotensin-Aldosterone System 3: 16-18 [Abstract]  
• Marin-Castano, M. E., Schanstra, J. P., Neau, E., Praddaude, F., Pecher, C., Ader, J.-L., Girolami, J.-P., Bascands, J.-L. (2002). Induction of Functional Bradykinin B1-Receptors in Normotensive Rats and Mice Under Chronic Angiotensin-Converting Enzyme Inhibitor Treatment. Circulation 105: 627-632 [Abstract] [Full Text]  
• Brown, N. J., Abbas, A., Byrne, D., Schoenhard, J. A., Vaughan, D. E. (2002). Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women. Circulation 105: 304-309 [Abstract] [Full Text]  
• Kansui, Y., Fujii, K., Goto, K., Abe, I. (2002). Bradykinin Enhances Sympathetic Neurotransmission in Rat Blood Vessels. Hypertension 39: 29-34 [Abstract] [Full Text]  
• Conti, V. R., McQuitty, C. (2001). Vasodilation and Cardiopulmonary Bypass : The Role of Bradykinin and the Pulmonary Vascular Endothelium. Chest 120: 1759-1761 [Full Text]  
• Suzuki, Y., Lopez-Franco, O., Gomez-Garre, D., Tejera, N., Gomez-Guerrero, C., Sugaya, T., Bernal, R., Blanco, J., Ortega, L., Egido, J. (2001). Renal Tubulointerstitial Damage Caused by Persistent Proteinuria Is Attenuated in AT1-Deficient Mice : Role of Endothelin-1. Am. J. Pathol. 159: 1895-1904 [Abstract] [Full Text]  
• Witherow, F. N., Helmy, A., Webb, D. J., Fox, K. A.A., Newby, D. E. (2001). Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure. Circulation 104: 2177-2181 [Abstract] [Full Text]  
• Campbell, D. J., Dixon, B., Kladis, A., Kemme, M., Santamaria, J. D. (2001). Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R1059-R1070 [Abstract] [Full Text]  
• TAAL, M. W., NENOV, V. D., WONG, W., SATYAL, S. R., SAKHAROVA, O., CHOI, J. H., TROY, J. L., BRENNER, B. M. (2001). Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone. J. Am. Soc. Nephrol. 12: 2051-2059 [Abstract] [Full Text]  
• Dendorfer, A., Rei{beta}mann, S., Wolfrum, S., Raasch, W., Dominiak, P. (2001). Potentiation of Kinin Analogues by Ramiprilat Is Exclusively Related to Their Degradation. Hypertension 38: 142-146 [Abstract] [Full Text]  
• Toto, R. (2001). Angiotensin II Subtype 1 Receptor Blockers and Renal Function. Arch Intern Med 161: 1492-1499 [Abstract] [Full Text]  
• Duka, I., Kintsurashvili, E., Gavras, I., Johns, C., Bresnahan, M., Gavras, H. (2001). Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension. Circ. Res. 88: 275-281 [Abstract] [Full Text]  
• Burnier, M. (2001). Angiotensin II Type 1 Receptor Blockers. Circulation 103: 904-912 [Full Text]  
• Raij, L. (2001). Workshop: Hypertension and Cardiovascular Risk Factors : Role of the Angiotensin II-Nitric Oxide Interaction. Hypertension 37: 767-773 [Abstract] [Full Text]  
• van Ampting, J. M. A., Hijmering, M. L., Beutler, J. J., van Etten, R. E., Koomans, H. A., Rabelink, T. J., Stroes, E. S. G. (2001). Vascular Effects of ACE Inhibition Independent of the Renin-Angiotensin System in Hypertensive Renovascular Disease : A Randomized, Double-Blind, Crossover Trial. Hypertension 37: 40-45 [Abstract] [Full Text]  
• Gainer, J. V., Stein, C. M., Neal, T., Vaughan, D. E., Brown, N. J. (2001). Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity. Hypertension 37: 46-51 [Abstract] [Full Text]  
• Cheetham, C., Collis, J., O'Driscoll, G., Stanton, K., Taylor, R., Green, D. (2000). Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 36: 1461-1466 [Abstract] [Full Text]  
• Murphey, L. J., Kumar, S., Brown, N. J. (2000). Endogenous Bradykinin and the Renin and Pressor Responses to Furosemide in Humans. J. Pharmacol. Exp. Ther. 295: 644-648 [Abstract] [Full Text]  
• Brown, N. J., Gainer, J. V., Murphey, L. J., Vaughan, D. E. (2000). Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor-Dependent, NO Synthase-Independent, and Cyclooxygenase-Independent Pathway. Circulation 102: 2190-2196 [Abstract] [Full Text]  
• Goto, K., Fujii, K., Onaka, U., Abe, I., Fujishima, M. (2000). Renin-Angiotensin System Blockade Improves Endothelial Dysfunction in Hypertension. Hypertension 36: 575-580 [Abstract] [Full Text]  
• Weinberg, M. S, Weinberg, A. J, Zappe, D. H (2000). Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. Journal of Renin-Angiotensin-Aldosterone System 1: 217-233  
• Conlin, P. R., Moore, T. J., Swartz, S. L., Barr, E., Gazdick, L., Fletcher, C., DeLucca, P., Demopoulos, L. (2000). Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients. Hypertension 36: 461-465 [Abstract] [Full Text]  
• Tamura, T., Said, S., Harris, J., Lu, W., Gerdes, A. M. (2000). Reverse Remodeling of Cardiac Myocyte Hypertrophy in Hypertension and Failure by Targeting of the Renin-Angiotensin System. Circulation 102: 253-259 [Abstract] [Full Text]  
• Grossman, E., Messerli, F. H., Neutel, J. M. (2000). Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors?. Arch Intern Med 160: 1905-1911 [Full Text]  
• Murphey, L. J., Hachey, D. L., Oates, J. A., Morrow, J. D., Brown, N. J. (2000). Metabolism of Bradykinin In Vivo in Humans: Identification of BK1-5 as a Stable Plasma Peptide Metabolite. J. Pharmacol. Exp. Ther. 294: 263-269 [Abstract] [Full Text]  
• Squire, I. B., O'Kane, K. P. J., Anderson, N., Reid, J. L. (2000). Bradykinin B2 Receptor Antagonism Attenuates Blood Pressure Response to Acute Angiotensin-Converting Enzyme Inhibition in Normal Men. Hypertension 36: 132-136 [Abstract] [Full Text]  
• McMurray, J., Berry, C. (2000). Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. Journal of Renin-Angiotensin-Aldosterone System 1: 131-136  
• Pfeffer, M. A (2000). Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?. Journal of Renin-Angiotensin-Aldosterone System 1: S41-S43 [Abstract]  
• Houle, S., Larrivee, J.-F., Bachvarova, M., Bouthillier, J., Bachvarov, D. R., Marceau, F. (2000). Antagonist-Induced Intracellular Sequestration of Rabbit Bradykinin B2 Receptor. Hypertension 35: 1319-1325 [Abstract] [Full Text]  
• Stys, T., Lawson, W. E., Smaldone, G. C., Stys, A. (2000). Does Aspirin Attenuate the Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Heart Failure?. Arch Intern Med 160: 1409-1413 [Abstract] [Full Text]  
• Siragy, H. M., de Gasparo, M., Carey, R. M. (2000). Angiotensin Type 2 Receptor Mediates Valsartan-Induced Hypotension in Conscious Rats. Hypertension 35: 1074-1077 [Abstract] [Full Text]  
• Duncan, A.-M., Kladis, A., Jennings, G. L., Dart, A. M., Esler, M., Campbell, D. J. (2000). Kinins in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278: R897-R904 [Abstract] [Full Text]  
• Schachter, M. (2000). ACE inhibitors, angiotensin receptor antagonists and bradykinin. Journal of Renin-Angiotensin-Aldosterone System 1: 27-29  
• Kim, S., Iwao, H. (2000). Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases. Pharmacol. Rev. 52: 11-34 [Abstract] [Full Text]  
• WAPSTRA, F. H., NAVIS, G., DE JONG, P. E., DE ZEEUW, D. (2000). Chronic Angiotensin II Infusion But Not Bradykinin Blockade Abolishes the Antiproteinuric Response to Angiotensin-Converting Enzyme Inhibition in Established Adriamycin Nephrosis. J. Am. Soc. Nephrol. 11: 490-496 [Abstract] [Full Text]  
• Dell’Italia, L. J., Oparil, S. (1999). Bradykinin in the Heart : Friend Or Foe?. Circulation 100: 2305-2307 [Full Text]  
• Luke, R. G. (1999). Hypertensive nephrosclerosis: pathogenesis and prevalence : Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant 14: 2271-2278 [Full Text]  
• Linz, W., Wohlfart, P., Scholkens, B. A, Malinski, T., Wiemer, G. (1999). Interactions among ACE, kinins and NO. Cardiovasc Res 43: 549-561 [Full Text]  
• Brown, N. J., Agirbasli, M., Vaughan, D. E. (1999). Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans. Hypertension 34: 285-290 [Abstract] [Full Text]  
• Davie, A. P., Dargie, H. J., McMurray, J. J. V. (1999). Role of Bradykinin in the Vasodilator Effects of Losartan and Enalapril in Patients With Heart Failure. Circulation 100: 268-273 [Abstract] [Full Text]  
• Brown, N. J., Gainer, J. V., Stein, C. M., Vaughan, D. E. (1999). Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature. Hypertension 33: 1431-1435 [Abstract] [Full Text]  
• Azizi, M., Agarwal, R., Gallois, H., Piot, O., Gainer, J. V., Brown, N. J. (1999). Bradykinin and Inhibition of Angiotensin-Converting Enzyme in Hypertension. NEJM 340: 967-969 [Full Text]  
• (1998). Is Bradykinin Important to ACE Inhibition?. Journal Watch Cardiology 1998: 8-8 [Full Text]  
• Marcic, B., Deddish, P. A., Skidgel, R. A., Erdos, E. G., Minshall, R. D., Tan, F. (2000). Replacement of the Transmembrane Anchor in Angiotensin I-converting Enzyme (ACE) with a Glycosylphosphatidylinositol Tail Affects Activation of the B2 Bradykinin Receptor by ACE Inhibitors. J. Biol. Chem. 275: 16110-16118 [Abstract] [Full Text]